hydrochlorothiazide + losartan or hydrochlorothiazide + lisinopril

This entry refers to the active comparator arms used in a Phase IV clinical trial (NCT00673790) sponsored by Forest Laboratories. The trial evaluated the blood pressure and metabolic effects of nebivolol compared to hydrochlorothiazide (HCTZ) when added to existing therapy with either an ACE inhibitor (lisinopril) or an angiotensin II receptor blocker (losartan). These combinations target hypertension through multiple pathways: HCTZ is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule; lisinopril is an ACE inhibitor that prevents the conversion of angiotensin I to angiotensin II; and losartan is an ARB that blocks the AT1 receptor. The study specifically focused on hypertensive patients with impaired glucose tolerance or impaired fasting glucose.

Brand names

HyzaarZestoreticPrinzide

Other names

HCTZ + losartanHCTZ + lisinopril